Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

nd involve risks and uncertainties as of the date of this release, including without limitation InterMune's expectation regarding its anticipated timing of concluding pricing and reimbursement discussions and/or initiating commercial launches for Esbriet in various European countries; the estimated size of the patient population in Canada suffering from IPF and InterMune's expectations with respect to Canada of securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans including the timing thereof; InterMune's expectation regarding the results of the ASCEND study and the prospects of success thereof and meeting the goal of bringing Esbriet to IPF patients in the United States;  InterMune's expectation in building its Esbriet franchise in North America; InterMune's intent to repurchase the remaining $18.4 million of the outstanding 2015 notes; and InterMune's projected revenue from sales of Esbriet and operating expenses for 2013.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 29, 2012 (the "Form 10-K"), most recent quarterly report on Form 10-Q filed with the SEC on November 9, 2012 (the "Form 10-Q"), and other periodic reports filed with the SEC, including but not limited to the following: (i) the risks related to the uncertain, lengthy and expensive clinical development process for the company's produc
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 24 marks ASEA's "Meet ASEA" grand ... manufacturer of the world's first and only redox signaling ... , The Mexico City event features renowned speakers Dr. ... Field Leader Shawn Catmull from Draper, UT. , Dr. ... from the University of Utah and devotes his career ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... offer and sell shares of its Common Stock and ... underwritten public offerings.  The Series A Convertible Preferred Stock ... Stock, provided that conversion will be prohibited if, as ... own more than 4.99% of the Common Stock then ...
(Date:9/17/2014)... 2014 A biodegradable polymer can ... as bacteria, fungi, and algae into smaller units ... inorganic compounds, carbon dioxide, and humus in a ... and improved costs, biodegradable polymers are proving to ... to conventional polymers. Primary factors that are responsible ...
(Date:9/17/2014)... Sept. 17, 2014 Intarcia Therapeutics, Inc. ... from a study of the cost and predictability of ... th Annual Meeting of the European Association for ... today, Christian Frois , Ph.D., of Analysis Group, ... of planned Intarcia-sponsored, retrospective studies to characterize the prevalence ...
Breaking Biology Technology:Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5
... 17 Initial public offerings for LinkedIn and Dunkin Donuts, takeovers of Mead Johnson Nutrition and Harley-Davidson, and a Cold Stone Creamery sale are among the 10 deals predicted by ... ... ... ...
... , March 17 Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that it has hired James ... ... ... ...
... ... Converting to 3D Imaging , ... Thornwood, N.Y. (PRWEB) March 17, 2010 -- Carl Zeiss, a leading provider ... recently announced two exciting online promotions. For a limited time, and only available online, ...
Cached Biology Technology:From Donuts To Hogs - Which Brand Icons Might Be In Play? 2From Donuts To Hogs - Which Brand Icons Might Be In Play? 3From Donuts To Hogs - Which Brand Icons Might Be In Play? 4From Donuts To Hogs - Which Brand Icons Might Be In Play? 5From Donuts To Hogs - Which Brand Icons Might Be In Play? 6From Donuts To Hogs - Which Brand Icons Might Be In Play? 7From Donuts To Hogs - Which Brand Icons Might Be In Play? 8Valeritas Announces Appointment of New CFO 2Valeritas Announces Appointment of New CFO 3Carl Zeiss Offers Online Promotions 2
(Date:9/16/2014)... (17 September, 2014)More than $100 trillion in cumulative ... annual carbon dioxide (CO2)a 40 percent reduction of ... if the world expands public transportation, walking and ... released by the University of California, Davis, and ... , Further, an estimated 1.4 million early ...
(Date:9/16/2014)... us that we inherit certain traits from our parents ... how these genes play out by taking certain drugs ... exactly what a team of researchers at the Boston ... research of epigenetics research. , Epigenetics regulates gene ... and histone proteins, which prevent permanent mutations or alterations ...
(Date:9/16/2014)... that spelled doom for the dinosaurs 66 million years ... a much greater extent than their deciduous peers, according ... are published in the journal PLOS Biology . ... of thousands of fossilized leaves of angiosperms ... to reconstruct the ecology of a diverse plant community ...
Breaking Biology News(10 mins):Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4
... Louis, MO, USA, February 1, 2009 A special ... Journal of the American Dietetic Association presents findings ... Study (SNDA-III), conducted by Mathematica Policy Research, Inc., as ... Sponsored by the Food and Nutrition Service of the ...
... leaders in tropical biology and conservation, William F. Laurance, ... and Thomas E. Lovejoy, research associate at the Institute ... Center for Science, Economics and the Environment, have won ... in Ecology and Conservation Biology, announced on 30 Jan. ...
... LA Huijing Xia, PhD, a postdoctoral research associate ... of Pharmacology at LSU Health Sciences Center New Orleans, ... a recently identified enzyme in the brain plays a ... pressure. The LSUHSC research team showed that Angiotensin-converting enzyme ...
Cached Biology News:Results of the third school nutrition dietary assessment study published 2Results of the third school nutrition dietary assessment study published 3Results of the third school nutrition dietary assessment study published 4Smithsonian scientists receive coveted BBVA Ecology and Conservation Award 2LSUSHC researchers find potential new target for hypertension treatment 2
... that it uses a deep-UV deuterium bulb, which ... with a shutter (controlled via a TTL signal ... DH-2000 Deuterium Tungsten Halogen Light Source combines ... light sources in a single optical path. The ...
One controller two vessel system suitable for early stage of fermentation, and small scale, Application : cultivation of microorganisms and human or animal cells...
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... used to reveal two distinct antigens in ... a Zymed polymer double staining detection method ... same human cell or tissue sample with ... using two different primary antibodies from mouse ...
Biology Products: